Article
The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
Journal of hypertension - 1 Oct 2002
Hallberg Pär, Karlsson Julia, Kurland Lisa, Lind Lars, Kahan Thomas, Malmqvist Karin, Ohman K Peter, Nyström Fredrik, Melhus Håkan
Abstract excerpt
BACKGROUND: The cytochrome P450 CYP2C9 enzyme (CYP2C9) metabolizes many clinically important drugs, for example, phenytoin, warfarin and the angiotensin II type 1 (AT(1)) receptor antagonists, losartan and irbesartan. Single nucleotide polymorphisms in the CYP2C9 gene result in the expression of three important variants, CYP2C9*1(wild-type), CYP2C9*2 and CYP2C9*3, the last two exhibiting reduced catalytic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.